<DOC>
	<DOCNO>NCT00407056</DOCNO>
	<brief_summary>The purpose phase 3 open-labeled study determine difluprednate ophthalmic emulsion effective treatment severe uveitis .</brief_summary>
	<brief_title>Study Difluprednate Ophthalmic Emulsion Treatment Severe Uveitis</brief_title>
	<detailed_description>The objective phase 3 study ass efficacy safety 0.05 % difluprednate ophthalmic emulsion patient severe endogenous anterior uveitis open-labeled , no-controlled no-randomized design .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Patients diagnosis endogenous anterior uveitis panuveitis Patients ≥ 50 anterior chamber cell observe slit lamp microscopy ( criterion evaluation sign 4 ) Patients require frequent instillation 0.1 % betamethasone sodium phosphate ophthalmic solution regular frequency specify dosage administration ( 3 4 times/day ) Patients age ≥ 12 year ( day obtain informed consent ) able actuate symptom Patients give write informed consent prior initiation study Patients meet inclusion criterion Patients initiate treatment systemic administration corticosteroid , nonsteroidal antiinflammatory drug , antiphlogistic enzyme immunosuppressive drug within 2 week instillation investigational drug Patients receive topical injection corticosteroid eye instillation investigational product ( solution formulation : within 1 week instillation investigational product , depot formulation : within 2 week instillation investigational product ) Patients receive instillation corticosteroid , nonsteroidal antiinflammatory ophthalmic solution antiphologistic enzyme within 12 hour instillation investigational drug Patients glaucoma ocular hypertension Patients corneal erosion corneal ulcer Patients viral , bacterial fungal keratoconjunctival disease suspect eye infection Patients allergy similar drug difluprednate Patients require use contact lens study period Women might pregnant , lactate woman Patients participate another clinical study within 3 month initiation present study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>